Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Summary

15 patients with PRP will be treated with guselkumab for 20 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit, week-4 visit, and week-24 visit. 3 visits in between these times and one follow up visit may be performed by secure videoconferencing.

Timeline

Start

2019-10-03

Primary completion

2022-08-11

Completion

2024-03-22

Publications

• Velasco RC, Shao C, Cutler B, Strunck J, Kent G, Cassidy PB, Choate K, Greiling TM. Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial. JAMA Dermatol. 2024 Jun 1;160(6):641-645. doi: 10.1001/jamadermatol.2024.0257.

Drugs

Indications